Oncolytics Biotech (ONCY) Tops Q1 EPS by 2c

Go back to Oncolytics Biotech (ONCY) Tops Q1 EPS by 2c

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024 4:01 PM EDT

Pelareorep advancing to registration-enabling studies

Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer

Overall survival data from BRACELET-1 breast cancer study expected in H2 2024

Cash position of $29.6 million provides runway through critical milestones into 2025

Management hosting conference call and webcast today at 4:30 p.m. ET

SAN DIEGO and CALGARY, AB,... More